scholarly journals WT1 epitope‑specific IgG and IgM antibodies for immune‑monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine

2022 ◽  
Vol 23 (2) ◽  
Author(s):  
Shouq Alzaaqi ◽  
Norifumi Naka ◽  
Kenichiro Hamada ◽  
Naoki Hosen ◽  
Mizuki Kanegae ◽  
...  
Keyword(s):  
Cancer Vaccine ◽  
Immune Monitoring ◽  
Igm Antibodies ◽  
Specific Igg ◽  
Advanced Sarcoma

scholarly journals Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans

Viruses ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 516
Author(s):  
Shuyi Yang ◽  
Keith R. Jerome ◽  
Alexander L. Greninger ◽  
Joshua T. Schiffer ◽  
Ashish Goyal
Keyword(s):  
Production Rate ◽  
Neutralizing Antibodies ◽  
Primary Infection ◽  
Natural Infection ◽  
Viral Clearance ◽  
Clinical Severity ◽  
Igg Antibodies ◽  
Igm Antibodies ◽  
Specific Igg ◽  
Specific Igg Antibodies

While SARS-CoV-2 specific neutralizing antibodies have been developed for therapeutic purposes, the specific viral triggers that drive the generation of SARS-CoV-2 specific IgG and IgM antibodies remain only partially characterized. Moreover, it is unknown whether endogenously derived antibodies drive viral clearance that might result in mitigation of clinical severity during natural infection. We developed a series of non-linear mathematical models to investigate whether SARS-CoV-2 viral and antibody kinetics are coupled or governed by separate processes. Patients with severe disease had a higher production rate of IgG but not IgM antibodies. Maximal levels of both isotypes were governed by their production rate rather than different saturation levels between people. Our results suggest that an exponential surge in IgG levels occurs approximately 5–10 days after symptom onset with no requirement for continual antigenic stimulation. SARS-CoV-2 specific IgG antibodies appear to have limited to no effect on viral dynamics but may enhance viral clearance late during primary infection resulting from the binding effect of antibody to virus, rather than neutralization. In conclusion, SARS-CoV-2 specific IgG antibodies may play only a limited role in clearing infection from the nasal passages despite providing long-term immunity against infection following vaccination or prior infection.

Diagnosis of rubella virus infections. I. A comparison between Vero and BHK-21 cells for the detection of specific IgG and IgM antibodies by immunofluorescence

1975 ◽  
Vol 21 (3) ◽  
pp. 289-292 ◽  
Author(s):  
Pierre Payment ◽  
Lucille Roy ◽  
Jean-Claude Gilker ◽  
André Chagnon
Keyword(s):  
Rubella Virus ◽  
Vero Cells ◽  
Virus Infections ◽  
Igm Antibodies ◽  
Specific Igg

Vero cells were more suitable then BHK-21 cells for the detection of rubella-specific 1gG antibodies because the nonspecific fluorescence was minimal. However, BHK-21 cells were found more sensitive than Vero cells for the detection of rubella-specific IgM antibodies.

A new method for the determination of virus specific IgG and IgM antibodies

1980 ◽  
Vol 66 (1) ◽  
pp. 67-70 ◽  
Author(s):  
W. A. K. Schmidt ◽  
Magdalena Klein
Keyword(s):  
New Method ◽  
Igm Antibodies ◽  
Specific Igg

Indirect ELISA for the detection of HSV-2 specific IgG and IgM antibodies with glycoprotein G (gG-2)

1992 ◽  
Vol 36 (3) ◽  
pp. 249-264 ◽  
Author(s):  
David W.T. Ho ◽  
Peter R. Field ◽  
Eva Sjögren-Jansson ◽  
Stig Jeansson ◽  
Anthony L. Cunningham
Keyword(s):  
Indirect Elisa ◽  
Igm Antibodies ◽  
Glycoprotein G ◽  
Specific Igg

scholarly journals Modeling flow cytometry data for cancer vaccine immune monitoring

2010 ◽  
Vol 59 (9) ◽  
pp. 1435-1441 ◽  
Author(s):  
Jacob Frelinger ◽  
Janet Ottinger ◽  
Cécile Gouttefangeas ◽  
Cliburn Chan
Keyword(s):  
Flow Cytometry ◽  
Cancer Vaccine ◽  
Immune Monitoring ◽  
Flow Cytometry Data ◽  
Modeling Flow

scholarly journals Microarray Analysis for a Comprehensive Immunological-Status Evaluation during Cancer Vaccine Immune Monitoring

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Vladia Monsurrò ◽  
Francesco M. Marincola
Keyword(s):  
Immune Responses ◽  
Cancer Vaccine ◽  
Single Cell Analysis ◽  
Immune Therapy ◽  
Immune Monitoring ◽  
Host Responses ◽  
Cell Analysis ◽  
Biological Mechanisms ◽  
High Throughput Gene Expression ◽  
Reductionist Approach

Anticancer immune responses can be enhanced by immune intervention that promotes complex biological mechanisms involving several cellular populations. The classical immune monitoring for biological-based cancer clinical trials is often based on single-cell analysis. However, the overall effect could be lost by such a reductionist approach explaining the lack of correlation among clinical and immunological endpoints often reported. Microarray technology could give the possibility of studying in a multiparametric setting the immune therapy effects. The application of microarray is leading to an improved understanding of the immune responses to tumor immunotherapy. In fact, analysis of cancer vaccine-induced host responses using microarrays is proposed as valuable alternative to the standard cell-based methods. This paper shows successful examples of how high-throughput gene expression profiling contributed to the understanding of anticancer immune responses during biological therapy, introducing as well the integrative platforms that allow the network analysis in molecular biology studies.

scholarly journals IMMUNOLOGICAL INVESTIGATIONS OF HHV-6 U12 AND U51 ENCODED PROTEINS INVOLVEMENT IN AUTOIMMUNE THYROIDITIS DEVELOPMENT

2020 ◽  
Author(s):  
Alina Sultanova ◽  
Maksims Cistjakovs ◽  
Liba Sokolovska ◽  
Egils Cunskis ◽  
Modra Murovska
Keyword(s):  
Amino Acid ◽  
G Protein ◽  
Autoimmune Thyroiditis ◽  
Synthetic Peptides ◽  
Human Herpesvirus ◽  
Amino Acid Sequences ◽  
G Protein Coupled Receptors ◽  
Igm Antibodies ◽  
Specific Igg ◽  
G Protein Coupled

AbstractHuman herpesvirus 6 (HHV-6) is a human pathogen with a wide cell tropism and many immunomodulating properties. HHV-6 has been linked to the development of multiple diseases, among them – autoimmune. Conflicting evidence implicates HHV-6 in autoimmune thyroiditis (AIT). HHV-6 contains two genes (U12 and U51) that encode putative homologues of human G-protein-coupled receptors (GPCR) like CCR1, CCR3 and CCR5. It has been shown that proteins encoded by HHV-6 U12 and U51 genes can be expressed on the surface of epithelial and some peripheral blood mononuclear cells populations, which makes them a potential cause for evoking autoimmunity.The aim of this study was to identify potentially immunogenic synthetic peptides derived from HHV-6 U12 and U51 amino acid sequences and to find evidences of the possible involvement of these proteins in AIT development. 62 AIT patients positive for HHV-6 infection were enrolled in this study. 30 different synthetic peptides designed from HHV-6 U12 and U51 proteins’ amino acid sequences, as well as, recombinant human CCR1, CCR3 and CCR5 proteins were used for suspension multiplex immunological assay (SMIA) to detect specific IgG, and IgM antibodies.HHV-6 peptide specific IgG and IgM antibodies were found in patient’s samples, with higher signals for IgM antibodies, which is indicative of reactivation and active HHV-6 infection. As well recombinant CCR1 and CCR5 showed high signals on IgM antibodies which is indicating on the presence of potential auto-antibodies against human G protein-coupled receptors. No cross reactivity between HHV-6 peptide specific antibodies and human recombinant CCR1, CCR3 and CCR5 was found, however, the possibility of cross-reactive autoantibodies specific for structural epitopes cannot be excluded.

Sign in / Sign up

Export Citation Format

Share Document